A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Abstract Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Megumi Kai, Angela N. Marx, Diane D. Liu, Yu Shen, Hui Gao, James M. Reuben, Gary Whitman, Savitri Krishnamurthy, Merrick I. Ross, Jennifer K. Litton, Bora Lim, Nuhad Ibrahim, Takahiro Kogawa, Naoto T. Ueno
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c37b0ab005ba4205ac526ecb4d11aff8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c37b0ab005ba4205ac526ecb4d11aff8
record_format	dspace
spelling	oai:doaj.org-article:c37b0ab005ba4205ac526ecb4d11aff82021-11-21T12:24:00ZA phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer10.1038/s41598-021-01473-22045-2322https://doaj.org/article/c37b0ab005ba4205ac526ecb4d11aff82021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01473-2https://doaj.org/toc/2045-2322Abstract Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 106 PFU/mL on day 1 (cycle 1), 108 PFU/mL on day 22 (cycle 2), and 108 PFU/mL every 2 weeks thereafter (cycles ≥ 3). Nine patients were enrolled, 6 with only locoregional disease and 3 with both locoregional and distant disease. No patient completed the planned 10 cycles or achieved complete or partial response. The median number of cycles administered was 4 (range, 3–8). Seven patients withdrew prematurely because of uncontrolled disease progression, 1 withdrew after cycle 3 because of fatigue, and 1 withdrew after cycle 4 for reasons unrelated to study treatment. Median progression-free survival and overall survival were 77 days (95% CI, 63–NA) and 361 days (95% CI, 240–NA). Two patients received 8 cycles with clinically stable disease as the best response. The most common grade 2 or higher adverse event was injection site reaction (n = 7, 78%). Future studies could examine whether combining intratumoral T-VEC with concurrent systemic therapy produces better outcomes.Megumi KaiAngela N. MarxDiane D. LiuYu ShenHui GaoJames M. ReubenGary WhitmanSavitri KrishnamurthyMerrick I. RossJennifer K. LittonBora LimNuhad IbrahimTakahiro KogawaNaoto T. UenoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Megumi Kai Angela N. Marx Diane D. Liu Yu Shen Hui Gao James M. Reuben Gary Whitman Savitri Krishnamurthy Merrick I. Ross Jennifer K. Litton Bora Lim Nuhad Ibrahim Takahiro Kogawa Naoto T. Ueno A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
description	Abstract Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 106 PFU/mL on day 1 (cycle 1), 108 PFU/mL on day 22 (cycle 2), and 108 PFU/mL every 2 weeks thereafter (cycles ≥ 3). Nine patients were enrolled, 6 with only locoregional disease and 3 with both locoregional and distant disease. No patient completed the planned 10 cycles or achieved complete or partial response. The median number of cycles administered was 4 (range, 3–8). Seven patients withdrew prematurely because of uncontrolled disease progression, 1 withdrew after cycle 3 because of fatigue, and 1 withdrew after cycle 4 for reasons unrelated to study treatment. Median progression-free survival and overall survival were 77 days (95% CI, 63–NA) and 361 days (95% CI, 240–NA). Two patients received 8 cycles with clinically stable disease as the best response. The most common grade 2 or higher adverse event was injection site reaction (n = 7, 78%). Future studies could examine whether combining intratumoral T-VEC with concurrent systemic therapy produces better outcomes.
format	article
author	Megumi Kai Angela N. Marx Diane D. Liu Yu Shen Hui Gao James M. Reuben Gary Whitman Savitri Krishnamurthy Merrick I. Ross Jennifer K. Litton Bora Lim Nuhad Ibrahim Takahiro Kogawa Naoto T. Ueno
author_facet	Megumi Kai Angela N. Marx Diane D. Liu Yu Shen Hui Gao James M. Reuben Gary Whitman Savitri Krishnamurthy Merrick I. Ross Jennifer K. Litton Bora Lim Nuhad Ibrahim Takahiro Kogawa Naoto T. Ueno
author_sort	Megumi Kai
title	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
title_short	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
title_full	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
title_fullStr	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
title_full_unstemmed	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
title_sort	phase ii study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c37b0ab005ba4205ac526ecb4d11aff8
work_keys_str_mv	AT megumikai aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT angelanmarx aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT dianedliu aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT yushen aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT huigao aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT jamesmreuben aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT garywhitman aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT savitrikrishnamurthy aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT merrickiross aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT jenniferklitton aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT boralim aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT nuhadibrahim aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT takahirokogawa aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT naototueno aphaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT megumikai phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT angelanmarx phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT dianedliu phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT yushen phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT huigao phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT jamesmreuben phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT garywhitman phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT savitrikrishnamurthy phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT merrickiross phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT jenniferklitton phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT boralim phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT nuhadibrahim phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT takahirokogawa phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer AT naototueno phaseiistudyoftalimogenelaherparepvecforpatientswithinoperablelocoregionalrecurrenceofbreastcancer
_version_	1718419092059193344

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Ejemplares similares